About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company committed to becoming a leader in the discovery, progression and advertising of next-generation cancer drugs. Athenex is organized around 3 platforms, adding an oncology innovation platform, an advertising platform and a global source chain platform. The company’s existing clinical portfolio is derived from 4 other platform technologies: (1) Orascovery, founded on glycoprotein inhibitor P, (2) inhibition of kinase src, (3) mobile T designed through T mobile receptors (TCR-T), and (4) arginine deprivation therapy. Athenex workers around the world are committed to the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Ill., Hong Kong; Taipei, Taiwan; several sites in Chongqing, China; Manchester, United Kingdom; Guatemala, Guatemala and Buenos Aires, Argentina. For more information, visit www.athenex.com.
About Sagard Holdings Sagard Holdings is a multi-strategy asset manager with professionals founded in Montreal, Toronto, New York, San Francisco, Paris and Singapore. Sagard seeks to generate exciting returns by combining investment opportunities with flexible capital responses and associating marketers with groups with in-depth industry knowledge. Sagard develops long-term partnerships and investment expansion through an exclusive global network of holding companies, sponsors, advisors and other vital relationships. Today, Sagard invests in 4 asset classes: personal equity, personal credit, royalties and venture capital. Sagard Holdings was founded through Power Corporation of Canada in 2005, in addition to its global investments.
Forward-looking statements
In the absence of old data, all statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements are sometimes referred to through terms such as “anticipate,” “believe,” “continue,” “you can also simply,” “estimate,” “expect,” “anticipate,” “target,” “guide,” “intend,” “likely,” “possibly,” “plan,” “prospective,” “anticipate,” “likely,” “probable,” “project,” “promising,” “look,” “should,” “would be,” and “would be” the actual effects possibly materially differ from those expressed or implied. Important points that can also cause actual effects to differ materially include: the level of progression of our leading clinical applicants and relevant threats related to drug progression, clinical trials, regulation, production and marketing; our reliance on third parties to succeed in certain spaces of Athenex’s business; our history of operating losses and a desire to raise more capital to continue trading; The insecurities surrounding our ability to comply with financing terms under our financing agreements and access to capital under them; the threats and insecurities relevant to the COVID-19 pandemic and its prospectus have an effect on our operations, money flow and monetary position; Competition Threats to intellectual assets Risks similar to those of foreign industry and China; the threat of slowing or disruption of production or other disruptions at our Chongqing facility; and other threat points defined from time to time in our filings with the SEC, copies of which will be lost rate in the Investor Relations segment of our online page at https://ir.athenex.com/phoenix.zhtml?c 254495 & p irol-sec or request from our Investor Relations Department. All data provided in this press release is as of the present date and we assume no legal liability and we do not intend to update any forward-looking statements, unless required by law.
CONTACTS Athenex, Inc. Daniel Lang, MD Business Development and Corporate Communications Email: [email protected]
Investor Relations: Tim McCarthy Managing Director, LifeSci Advisors, LLC Email: [email protected]
Sagard Holdings Media Inquiries: Adam Daifallah Email: [email protected]
Investor Relations: Leslie Hill Email: [email protected]